ERBB2 and breast cancer: There was an increase in the use of chemotherapy and trastuzumab among patients with HER2-positive T1a tumors over the past decade, especially after the report of the pivotal trial of trastuzumab in patients with small, node-negative, HER2-positive breast cancer [15, 16].